Thomas Keller

Thomas has over 25 years of experience in drug discovery at Novartis and A*STAR. He currently serves as an Investment Partner at Trinity Innovation Bioventure Singapore (TIBS). Previously, he was Head of Chemistry and Deputy Director at the Experimental Therapeutics Centre (ETC), A*STAR, and Director of Discovery Chemistry at the Experimental Drug Development Centre (EDDC), A*STAR. Prior to A*STAR, Dr. Keller held key leadership positions as the Head of Chemistry at the Novartis Respiratory Research Centre (UK); Head of Chemistry and Deputy Director at the Novartis Institute for Tropical Diseases (Singapore). Dr. Keller was instrumental in setting up industrial drug discovery research groups at Novartis and ETC, which were responsible for the delivery of clinical development compounds such as Cipargamin (Malaria, Phase 2), Indacaterol (Respiratory, marketed) and ETC-159 (Cancer, Phase 1).

Thomas holds a Ph.D. in Organic Chemistry from the University of British Columbia, Canada.